Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.
Why It Matters
Rayobic could dramatically extend survival for patients with lethal CNS cancers, addressing a decades‑long therapeutic void and reshaping oncology investment priorities.
Key Takeaways
- •Plus Therapeutics pivoted to radiotherapy for CNS cancers in 2019.
- •Rayobic employs Re‑186 beta emitter delivering tenfold radiation doses.
- •Therapeutic index estimated at 100:1, vastly surpassing competitors.
- •Phase‑1 trials show safety and dose‑dependent survival gains.
- •Virtual development model integrates diagnostics via C‑inside Diagnostics subsidiary.
Summary
In a recent Life Science Leader interview, Marc Hedrick, M.D., President and CEO of Plus Therapeutics, outlined the company’s strategic shift toward radiotherapeutics targeting central nervous system (CNS) malignancies. The discussion centered on the lead asset, Rayobic, a Re‑186 beta‑emitting radiopharmaceutical designed to overcome the dose‑limiting constraints of conventional external‑beam radiation.
Hedrick explained that CNS cancers have seen stagnant survival improvements over four decades, making high‑dose, targeted radiation the most effective existing modality. Rayobic’s formulation delivers up to 740 Gy—roughly ten times the dose achievable with standard fractionated therapy—while maintaining a therapeutic index estimated at 100:1. Phase‑1 data in glioblastoma and leptomeningeal disease show no dose‑limiting toxicities and a clear correlation between incremental gray units and extended survival.
The CEO highlighted the company’s “virtual” development model, leveraging a diagnostic arm, C‑inside Diagnostics, to identify suitable patients and streamline trial execution. He noted, “We have not yet reached a maximum therapeutic dose; each additional gray improves outcomes,” underscoring the platform’s safety and potency. The integration of advanced analytics, diagnostics, and radiopharmaceutical engineering positions Plus Therapeutics as a potential disruptor in a historically underserved market.
If Rayobic’s promising early‑stage results translate into later‑phase success, the therapy could redefine standards of care for glioblastoma, leptomeningeal metastases, and pediatric brain tumors, attracting significant investor capital and prompting broader industry investment in high‑dose, targeted radiotherapy solutions.
Comments
Want to join the conversation?
Loading comments...